Concepedia

Rich Woessner

RW

13

Publications

570

Citations

12

H-Index

1987

Active since

Affiliations

Blueprint Medicines (United States)(Current)

Array BioPharma (United States)

Yonsei University

Rich Woessner is an author at Blueprint Medicines (United States) specializing in medicine, pharmacology, and drug discovery.

Top concepts

Publications per year

1987–2024

13

Publications

13

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

Meredith S. Eno, Jason D. Brubaker, John E. Campbell et al. · Journal of Medicinal Chemistry · 2022 · 146 citations · Full text

Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response

Ben Sidders, Pei Zhang, Kelly Goodwin et al. · Clinical Cancer Research · 2020 · 96 citations

Potent and selective pyrazole-based inhibitors of B-Raf kinase

Joshua D. Hansen, Jonas Grina, Brad Newhouse et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 65 citations · Full text

, , +6

1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC

Stefanie S. Schalm, Tom Dineen, Sangbin Lim et al. · Annals of Oncology · 2020 · 50 citations · Full text

, , +6

Non-oxime pyrazole based inhibitors of B-Raf kinase

Bradley J. Newhouse, Joshua D. Hansen, Jonas Grina et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 44 citations · Full text

, , +4

Rows per page

1–5 of 13